GLPwatch
Papers (10404)
Page 80 of 174, ranked by citation count.
- Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
- Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients.
- Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
- Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis.
- Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.
- An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
- Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus.
- Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.
- Targeted pH switched europium complexes monitoring receptor internalisation in living cells.
- Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms.
- Pro-healing impact of liraglutide on skin wounds in normoglycemic mice.
- Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
- Pre-Clinical Evaluation of a Modified Cyclodextrin-Based Nanoparticle for Intestinal Delivery of Liraglutide.
- Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.
- Reduced expression of ERp46 under diabetic conditions in β-cells and the effect of liraglutide.
- Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice.
- Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity.
- The glucagon-like peptide 1 receptor agonist Exendin-4 induces tenogenesis in human mesenchymal stem cells.
- The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
- Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?
- A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.
- Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.
- Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.
- An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program.
- Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity.
- Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia.
- Liraglutide preconditioning attenuates myocardial ischemia/ reperfusion injury via homer1 activation.
- Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.
- Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
- Safety of injectable semaglutide for type 2 diabetes.
- Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.
- Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
- Semaglutide for obesity: four STEPs forward, but more to come.
- Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
- Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.
- Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3.
- Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.
- Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis.
- Exenatide Regulates Substrate Preferences Through the p38γ MAPK Pathway After Ischaemia/Reperfusion Injury in a Rat Heart.
- Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease.
- Overview of new antiobesity drugs.
- Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial.
- Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
- Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.
- Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer's disease.
- Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus.
- Role of Vasopressin in the Regulation of Renal Sodium Excretion: Interaction with Glucagon-Like Peptide-1.
- Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study.
- GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment.
- Exendin-4 regulates GLUT2 expression via the CaMKK/CaMKIV pathway in a pancreatic β-cell line.
- Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
- Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: a retrospective cohort study.
- Intelligent Escape System for the Oral Delivery of Liraglutide: A Perfect Match for Gastrointestinal Barriers.
- GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state <i>via</i> GSK-3β pathway.
- Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes.
- Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis.
- Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.
- IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience.
- Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?